Cargando…

Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy

Detalles Bibliográficos
Autores principales:	Crombie, Jennifer L., Jacobson, Caron A., Redd, Robert, Shouse, Geoffrey, Herrera, Alex F., Chow, Victor A., Gauthier, Jordan, Mullane, Erin, Cahill, Kirk, Kline, Justin, Romancik, Jason, Cohen, Jonathon B., Saucier, Anna, Houot, Roch, Armand, Philippe, Hess, Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690912/ https://www.ncbi.nlm.nih.gov/pubmed/37259597 http://dx.doi.org/10.3324/haematol.2022.282345

Ejemplares similares

Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients
por: Aleissa, Muneerah M., et al.
Publicado: (2023)

Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma
por: Merryman, Reid W., et al.
Publicado: (2023)

Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
por: Houot, Roch, et al.
Publicado: (2020)

T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances
por: Messéant, Ondine, et al.
Publicado: (2021)

Born to survive: how cancer cells resist CAR T cell therapy
por: Lemoine, Jean, et al.
Publicado: (2021)

Diffuse Large B-Cell Lymphoma’s New Genomics: The Bridge and the Chasm
por: Crombie, Jennifer L., et al.
Publicado: (2020)

Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody
por: Houot, Roch, et al.
Publicado: (2012)

CAR-T cells and BiTEs in solid tumors: challenges and perspectives
por: Edeline, Julien, et al.
Publicado: (2021)

A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell–associated neurotoxicity syndrome
por: Jacobson, Caron A., et al.
Publicado: (2023)

“Chronic myelogenous leukemia in primary blast crisis” rather than “de novo BCR‐ABL1‐positive acute myeloid leukemia”
por: Pastoret, Cedric, et al.
Publicado: (2017)

Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy
por: Amidi, Yalda, et al.
Publicado: (2022)

Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists
por: Drillet, Gaëlle, et al.
Publicado: (2022)

Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy
por: Johnson, P Connor, et al.
Publicado: (2022)

Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy
por: de Charette, Marie, et al.
Publicado: (2018)

Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma
por: Little, Jessica S., et al.
Publicado: (2022)

Renal Dysfunction in Patients With Direct Infiltration by B-Cell Lymphoma
por: Corlu, Lea, et al.
Publicado: (2019)

Development of a combined positron emission mammograph and ultrasound scanner
por: Frisch, Benjamin Armand
Publicado: (2012)

Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation
por: Merryman, Reid W., et al.
Publicado: (2022)

A Case Report of Nongerminal Center B-Cell Type Diffuse Large B-Cell Lymphoma Treated to Complete Response with Rituximab and Ibrutinib
por: Shouse, Geoffrey, et al.
Publicado: (2018)

Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti‐CD19 chimeric antigen receptor T‐cell efficacy
por: Guidetti, Anna, et al.
Publicado: (2022)

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma
por: Timmerman, John, et al.
Publicado: (2020)

Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?
por: Chiappella, Annalisa, et al.
Publicado: (2019)

Donor Recipient Chimeric Cells Induce Chimerism and Extend Survival of Vascularized Composite Allografts
por: Cwykiel, Joanna, et al.
Publicado: (2021)

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

Central tolerance promoted by cell chimerism
por: Zeleniak, Ann, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

P887: PROGNOSTIC VALUE OF POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
por: Tamariz-Amador, Luis-Esteban, et al.
Publicado: (2023)

Impact of COVID-19 Pandemic on Hematopoietic Stem Cell Transplantation (HSCT) and Immune Effector Cell (IEC) Therapies: A Large US Cancer Center Experience
por: Maurer, Katie, et al.
Publicado: (2021)

Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study
por: Epperla, Narendranath, et al.
Publicado: (2023)

Lysosomal cathepsin creates chimeric epitopes for diabetogenic CD4 T cells via transpeptidation
por: Reed, Brendan, et al.
Publicado: (2020)

Tetraploid embryonic stem cells can contribute to the development of chimeric fetuses and chimeric extraembryonic tissues
por: Wen, Bingqiang, et al.
Publicado: (2017)

Chimeric Antigen Receptor T Cell Therapy in Hematology
por: Ataca, Pınar, et al.
Publicado: (2015)

Chimeric Antigen Receptor T-Cells: The Future Is Now
por: Mchayleh, Wassim, et al.
Publicado: (2019)

Chimeric RNA in Cancer and Stem Cell Differentiation
por: Elfman, Justin, et al.
Publicado: (2018)

Chimeric Antigen Receptor beyond CAR-T Cells
por: Qin, Vicky Mengfei, et al.
Publicado: (2021)

Landscape of Chimeric RNAs in Non-Cancerous Cells
por: Chen, Chen, et al.
Publicado: (2021)

Engineering better chimeric antigen receptor T cells
por: Zhang, Hao, et al.
Publicado: (2020)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
por: Galli, Eugenio, et al.
Publicado: (2021)

Humanized Chimeric Antigen Receptor (CAR) T cells
por: Kozani, Pouya Safarzadeh, et al.
Publicado: (2021)

Chimeric nanoparticles for targeting mitochondria in cancer cells
por: Bajpai, Aman, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t8fflmrkaq4aom7psk4b58qr18